Dennis Morris, MD
Interventional Cardiology · Greenville, NCNPI 1215998083
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,000 of the $8,863 with a category attached, or 79.0%. Abiomed accounts for 96.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $7,588 and has fallen 99.6% since, to $32 in 2025.
Across 17 payments — averaging $521.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$9K
- GE HealthCare$148
- Boston Scientific$73
- Cordis US CORP.$32
- Shockwave Medical, Inc$21
Across 14 payments — averaging $1929.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$27K
What the payments were for
- Speaking & faculty fees$7,00079%
- Travel & lodging$1,02812%
- Food & beverage$6878%
- Education$1482%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 10 | $8,588 |
| GE HealthCare | 1 | $148 |
| Boston Scientific | 3 | $73 |
| Cordis US CORP. | 2 | $32 |
| Shockwave Medical, Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$8,568
How this compares
$8,863 in reported general payments places this provider in the 65th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $23,153 |
| EntrestoSacubitril/Valsartan | 15 | $10,416 |
| Metoprolol Succinate | 11 | $276 |
| Carvedilol | 15 | $208 |
| Amlodipine Besylate | 12 | $168 |
| Atorvastatin Calcium | 29 | $164 |
| Metoprolol Tartrate | 25 | $110 |
| Ezetimibe | 11 | $108 |
| ClopidogrelClopidogrel Bisulfate | 15 | $91 |
| Furosemide | 11 | $30 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Greenville
- Paul MahoneyGreenville$1.7M
- Neeraj ShahGreenville$28K
- Eric CarlsonGreenville$26K
- Muhammad TariqGreenville$16K
- George AdamsGarner$4.1M
- Ravish SacharRaleigh$1.6M
- Patrick SimpsonPinehurst$579K
- Ronald UszenskiMooresville$495K
- Oluseun AlliCharlotte$485K
- Matthew CavenderChapel Hill$453K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.